Can Ozempic Treat PCOS?

Ozempic is not approved to treat PCOS, and no GLP-1 receptor agonist is approved specifically for PCOS in U.S. labels. Ozempic is a type 2 diabetes medicine; the obesity version of the same drug, semaglutide, is sold as Wegovy. Neither label lists PCOS. What the evidence does support is narrower and still useful: in women whose PCOS runs alongside higher weight or insulin resistance, semaglutide has produced weight loss and improved metabolic markers in short studies, and some studies also report improvement in irregular periods and androgen measures. Whether the drug treats PCOS itself, or mainly treats weight and insulin resistance, remains unanswered.

The metabolic evidence is strongest

For weight, GLP-1 drugs have the clearest edge over metformin, a long-standing insulin-sensitizing option. Across randomized trials and reviews in women with PCOS, the most repeatable signal is lower weight, BMI, and waist measures, with insulin-resistance markers improving in many analyses. In a 2025 randomized open-label trial, 100 overweight or obese women with PCOS were assigned to metformin alone or metformin plus semaglutide, and 80 completed 16 weeks. Among completers, the semaglutide group lost about 6 kg, compared with about 2 kg on metformin alone, and had larger reductions in BMI, waist-to-hip ratio, and testosterone. Insulin resistance improved in both groups, but the between-group difference for that marker was not clearly significant. A 2023 uncontrolled semaglutide study reported larger losses among participants who responded and stayed on treatment for six months. This is the strongest, most consistent finding in the literature, and it is the reason the drug is worth considering at all.

The 2023 International Evidence-based PCOS Guideline reflects exactly this. It says anti-obesity medications, semaglutide included, can be considered only as an add-on to active lifestyle change for managing higher weight, following general obesity guidance. That is a floor, not a ceiling. If you have PCOS with higher weight or clear insulin resistance, the metabolic case for discussing a GLP-1 drug is reasonable, not because it is an official PCOS therapy, but because it targets a common metabolic driver.

Periods and testosterone: promising, not proven

For symptoms, the signal is encouraging but not decisive. A newer 2026 randomized trial adding semaglutide to metformin and lifestyle care reported the same direction: more women got their cycles back than with metformin and lifestyle care alone. In the 2023 uncontrolled semaglutide study, many participants who responded to treatment and continued for six months reported normal menses. In a small two-year follow-up, lower free testosterone persisted after semaglutide was stopped while several cardiometabolic gains moved back toward baseline. That hints the androgen effect may be more than a passing consequence of weight loss, though it is still one small uncontrolled follow-up.

The limit is the trial quality. Nearly all of these studies are small, short, single-center, and often open-label, with menstrual and hormone results often reported outside the main weight outcome. They are enough to say the direction is favorable and consistent. They are not enough to call semaglutide a treatment for PCOS itself, distinct from treating the weight and insulin resistance that often travel with it.

The fertility question is not settled

The loudest claim is that Ozempic restores fertility. Earlier exenatide trials and reviews reported higher pregnancy or ovulation rates. But semaglutide trials have not established a live-birth benefit, and older GLP-1 fertility data are limited. The improvement plausibly reflects restored ovulation after weight loss, an opened door rather than a direct fertility drug, and current trial designs cannot separate the two. Larger multicenter trials that follow women through to live birth would settle it; until then, treat semaglutide as a way to improve the metabolic conditions for conceiving, not as a proven fertility treatment.

If pregnancy is possible, the timing rules matter

This is the one place the caution is not just bureaucratic. GLP-1 drugs have not been shown safe in early pregnancy. One large pregnancy cohort, mostly in women with obesity, found that GLP-1 receptor agonist exposure before conception or early in pregnancy, followed by stopping, was associated with greater gestational weight gain and higher rates of preterm delivery, gestational diabetes, and hypertensive disorders. That study was observational and not PCOS-specific, so it cannot prove the drug caused those outcomes, and other pregnancy-exposure analyses have not shown a consistent risk signal. Still, the practical rule is clear: contraception is required during treatment, and the Ozempic label advises stopping at least two months before a planned pregnancy. You may ovulate again after weight loss even if you assumed you couldn't conceive. If pregnancy is possible, that has to be planned around, not discovered. For reproductive goals specifically, the PCOS guideline still recommends anti-obesity drugs only in research settings.

One more thing to weigh: the benefit often fades after stopping. In general GLP-1 discontinuation studies, weight regain is common; in a small PCOS follow-up where women stayed on metformin, some benefit persisted but weight still moved back upward. That makes these medicines a longer-term commitment for the metabolic side of PCOS, not a quick course. If your PCOS is driven by higher weight and insulin resistance, semaglutide is a reasonable, evidence-backed prescription option to discuss. What it is not, on current evidence, is a cure for PCOS or a proven path to a live birth.